10x Genomics Surges Past $42 on Proteintech Deal Euphoria — But Can an Unprofitable Company Justify This Rally?

Shares of 10x Genomics (TXG) jumped 12.9% to $42.32 on July 9, blowing past a 52-week high the stock had only just set days earlier, as investors continue to price in the strategic upside of the company's June 9 acquisition of Proteintech Genomics. No fresh headlines accompanied the move — this is pure deal digestion, with Wall Street increasingly convinced the buy reshapes the company's competitive position in biological research tools.

• The Deal Fills a Gap Researchers Already Wanted Filled. Proteintech Genomics' protein panels were purpose-built for 10x's single-cell workflows and are already used by many researchers to simultaneously analyze RNA and protein. That matters because integration risk on the product side looks relatively contained compared with buying a completely separate platform. Essentially, 10x bought a bolt-on business that already runs on its own machines — meaning the company can start selling these panels to its existing customer base almost immediately, with minimal technical friction.

• Analysts Are Racing to Raise Targets, But the Stock Has Outrun Most of Them. Citi raised its price target to $45 from $24 , while Barclays raised to $40 from $30, keeping an Overweight rating.

Canaccord reiterated a Buy at $32. At $42.32, TXG now trades above two of those three targets — a sign the market is pricing in execution the Street hasn't fully modeled yet.

• The Balance Sheet Supports Dealmaking, But Profitability Remains Elusive. 10x ended Q1 2026 with $539.8 million in cash and marketable securities , and financial terms of the acquisition were not disclosed.

The company reported EPS of negative $0.10 in Q1 2026, improved from negative $0.28 a year earlier , while full-year 2026 revenue guidance sits at $600–$625 million. Losses are narrowing, but this remains a stock priced on future promise, not current profits.

• The Bigger Bet Is Becoming the One-Stop Shop for Cell Biology. This acquisition, coming after the Q1 2026 launch of a new spatial biology platform and the 2025 acquisition of Scale Biosciences, demonstrates a concerted effort to broaden the company's technological capabilities.

Peers such as NanoString, Standard BioTools, and Illumina are also competing to be the default partner for large labs — and the race to bundle gene, protein, and spatial data into one ecosystem will define who captures long-term research spending. For shareholders, today's rally is a vote of confidence in that vision; whether the revenue follows is the question that matters next.